和田多长时间能取环(和田包皮过长手术费用流程) (今日更新中)

ULAN BATOR, Aug. 2 (Xinhua) -- The Mongolian government has confirmed equine influenza, a disease that mainly affects horses, broke out in 14 provinces.The government's news office announced the confirmation Tuesday after suspected cases were recently discovered in 18 provinces of the country, where horses still play a key role.According to a Mongolian government report, Mongolian Vice Premier M. Enkhbold called a state emergency situation committee meeting on Monday to respond to the epidemic.Millions of horses will need to be vaccinated, given cases of the disease have been discovered in all but three provinces -- Bayan-Ulgii, Zavkhan and Umnugobi.Equine influenza usually broke out in spring and fall, said an official of the Mongolian veterinarian and breeding bureau. He urged vaccination to be carried out as soon as possible.Mongolia has experienced several equine influenza outbreaks in the past few decades. Outbreaks in Khovd province in 2007 and 2008 caused huge losses to the local livestock industry.Animal husbandry is a dominant factor in the agriculture sector of Mongolia, which has more than 40 million livestock, 2 million of which are horses.

WASHINGTON, Aug. 24 (Xinhua) -- Online search engine Google Inc. has agreed to pay 500 million U.S. dollars to settle claims that it allowed online Canadian pharmacies to place advertisements targeting consumers in the United States, U.S. Justice Department announced Wednesday.The settlement, one of the largest ever in the United States, represents the gross revenue received by Google as a result of Canadian pharmacies advertising through Google's AdWords program, plus gross revenue made by Canadian pharmacies from their sales to U.S. consumers.The advertisements led to illegal imports of prescription drugs into the country, the Justice Department said.The shipment of prescription drugs from pharmacies outside the United States to customers in the United States typically violates the Federal Food, Drug and Cosmetic Act and in the case of controlled prescription drugs, the Controlled Substances Act.Google was aware as early as 2003, that generally, it was illegal for pharmacies to ship controlled and non-controlled prescription drugs into the United States from Canada."The Department of Justice will continue to hold accountable companies who in their bid for profits violate federal law and put at risk the health and safety of American consumers," Deputy Attorney General James Cole said in a statement."This settlement ensures that Google will reform its improper advertising practices with regard to these pharmacies while paying one of the largest financial forfeiture penalties in history," he said.Google had previously set aside that amount for a possible settlement over its advertising practices, according to a regulatory filing in May.

BEIJING, Aug. 30 (Xinhuanet) -- The United Nations is warning authorities to be on high alert of bird flu as the virus appears to be returning.The UN Food and Agriculture Organization said in a statement Monday a mutant strain is spreading across parts of Asia, and there could be a spill-over to humans.However, it said at this stage, there's no need for any alarm.A mutant strain of H5N1, which can apparently sidestep defenses of existing vaccines, is spreading in China and Vietnam, it said.It said the variant of the virus appears able to side step Vaccines.The UN is concerned the new form of the virus could spread to Cambodia, Thailand and Malaysia, as well as the Korean Peninsula and Japan."Wild birds may introduce the virus, but people's actions in poultry production and marketing spread it," said FAO's chief veterinary office Juan Lubroth in urging greater preparedness and surveillance, according to media reports.Outbreaks of the virus peaked in 2006 before it was eradicated from most countries.

LOS ANGELES, June 5 (Xinhua) -- U.S. researchers have developed two new drugs that can prolong the lives of patients with advanced melanoma, it was announced on Sunday.Research on both drugs was presented at the on-going annual meeting of the American Society of Clinical Oncology in Chicago, according to HealthDay News.This is the first big news in years for treatment of melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure, the report said.The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration.The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March."The March FDA approval of ipilumumab (Yervoy) was the first new drug approval for melanoma in 13 years," said Tim Turnham, executive director of the Melanoma Research Foundation.The two drugs were developed by researchers at Memorial Sloan- Kettering Cancer Center in New York City, the report said."This is really a huge step toward personalized care in melanoma," Dr. Paul Chapman, lead author of the first study and the attending physician in the melanoma/sarcoma service at Memorial Sloan-Kettering, said in a statement. "This (vemurafenib) is the first successful melanoma treatment tailored to patients who carry a specific gene mutation in their tumor, and could eventually become one of only two drugs available that improves overall survival in advanced cancers.""Having two trials that show a benefit in survival in patients with melanoma, both of these in first-line settings -- we weren't here just a few years ago," said Dr. Stephen Hodi, director of the Melanoma Center at Dana Farber Cancer Institute in Boston. "These are huge, paradigm-shifting results for the field."In the vemurafenib trial, sponsored by the drug's makers, researchers randomly assigned 675 patients with advanced, inoperable melanoma to receive either the chemotherapy drug dacarbazine or vemurafenib. Vemurafenib targets the V600E mutation in the BRAF gene.At the three-month mark, patients taking vemurafenib were 63 percent less likely to die and 74 percent less likely to die or see their cancer return, compared to patients taking dacarbazine alone.Few patients had side effects in the vemurafenib group, although some did develop squamous cell carcinoma, a less dangerous form of skin cancer.This is the first drug that has been proven superior to chemotherapy in this group of hard-to-treat patients, the researchers said."There was such a substantial benefit that we recommended that patients cross over," Chapman said at a Sunday news briefing. "It' s unprecedented to report a trial this early. The median follow-up time was three months." Yet the differences between the two groups became evident almost immediately.Dr. Lynn Schuchter, co-moderator of the briefing and division chief of hematology-oncology at Abramson Cancer Center of the University of Pennsylvania in Philadelphia, said symptoms subsided in some patients almost immediately, enabling them to cut back on pain medication in just 72 hours."The median time to progression with dacarbazine was 1.6 months versus three months with vemurafenib, which is a huge difference," said Chapman.In the second study, about 500 patients were randomly picked to receive Yervoy plus dacarbazine or dacarbazine alone.Those taking both drugs lived a median of 11.2 months compared to 9.1 months for those taking dacarbazine alone. Time to recurrence of disease was about the same for both groups: 2.8 months and 2.6 months, respectively.Almost half of those taking the combination therapy were alive after one year, compared to 36.3 percent in the other group. After two years, the rates were 28.5 percent and 17.9 percent, respectively.By three years out, 20.8 percent of those in the combination group were alive compared with 12.2 percent of those taking chemotherapy alone.This is the first study to combine chemotherapy and immunotherapy both safely and effectively.A study to test vemurafenib in combination with Yervoy has already begun, according to HealthDay News.

BEIJING, Sept. 2 (Xinhuanet) -- Firefighters who worked in the wreckage of the World Trade Center in 2001 were 19 percent more likely to develop cancer than those who were not there, according to a study.The study, published Thursday in the British medical journal The Lancet, surveyed cancer occurrence in nearly 10,000 male firefighters in the seven years after Sept. 11, 2001. (There were too few women to create a meaningful sample size.)The 9/11 attacks occurred on Tuesday, Sept. 11, 2001. As a result, the World Trade Center collapsed, and nearly 3,000 Americans killed. Among the 2,753 victims killed in the World Trade Center were 343 firefighters.There were 263 cancer cases in the exposed population, showing a cancer rate 19 percent higher than that of the group not exposed.The study indicated that cancers like melanoma, non-Hodgkin’s lymphoma, thyroid and prostate cancer occurred more frequently among exposed firefighters than in the general population. But occurrences of lung cancer did not increase.The findings “provide information that there may be a significant cancer risk for these people”, said Dr. James Melius, the administrator of the New York State Laborers’ Health and Safety Trust Fund and one of the peer reviewers of the study.But the results were far from conclusive. “This is not an epidemic,” said Dr. David J. Prezant, a lead researcher and the chief medical officer for the New York Fire Department.

来源：资阳报